DRKS00031033Enrolling By InvitationUnknown
Improvement of immune status, parasympathetic response, body composition and fascial elasticity in stressed persons by applying cryotherapy in a cold chamber at minus 90 degrees - ACT Immune Study
Stiftung Immunweltmeister e. V.0 个研究点目标入组 20 人开始时间: 2023年5月16日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- Enrolling By Invitation
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 45 Years 至 75 Years（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Contraindications for whole-body cryotherapy are the following: pregnancy, severe hypertension (blood pressure > 180/100), acute or recent myocardial infarction, unstable angina, arrhythmia, symptomatic cardiovascular disease, pacemaker, peripheral arterial occlusive disease, venous thrombosis, acute or recent cerebrovascular accident, uncontrolled seizures, Raynaud's syndrome, fever, tumor disease, symptomatic lung disease, Blood clotting disorders, severe anemia, infections, cold allergies and acute kidney and urinary tract diseases, as well as epileptic seizures, further increased intraocular pressure. If you suffer from the above conditions or meet the exclusion criteria, you will unfortunately not be able to participate in our study, as we cannot guarantee that cryotherapy can have positive effects for you. The same applies to patients with glaucoma, for which there is no exclusion of liability, e.g. in case of unexplained increase in intraocular pressure. Exclusion criteria for the study are more than 4 cups of coffee per day, more than 2 alcoholic beverages per day, a strong diet change and extreme sports, as well as other cold applications such as ice bathing.
研究者
相似试验
招募中
2 期
An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma incorporating Iberdomide, Isatuximab, and Dexamethasone (Iber-IsaDex) – the IBIS studyBlood - Haematological diseasesMultiple MyelomaACTRN12621001037897Australasian Myeloma Research Consortium50
已完成
Unknown
Efficacy and safety evaluation of PPCE for immune enhancement in healthy adults.KCT0008678MnF Korea30
进行中（未招募）
不适用
(Maraviroc ENHancement of Immunological Response): A pilot study of maraviroc as an add-on in patients with reduced CD4 cell count despite full viral suppression - MENHIREUCTR2010-019518-25-ITAZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO (A.O. DI RILIEVO NAZIONALE)
已完成
2 期
Immune responses, boosting effects of adults previously received two doses of inactivated COVID-l9 vaccines and third doses of any COVID-I9 vaccine with additional mRNA COVID-19 vaccine boost after one yearPrimary Objectives:To evaluate the antibody responses and long-term immunogenicity both humoral and T-cell response after boosting of bivalent mRNA vaccine approximately one year of those who have previously received two doses of Sinovac or Sinoharm and third or forth doses of COVID vaccines of any platforms during the current Omicrons variants.SafetyTo assess the safety and tolerability of the mRNA booster doseSinovac or Sinoharm and third or forth doses of COVID vaccinesmRNA boostTCTR20230811004ational Research Council of Thailand (NRCT)198
进行中（未招募）
不适用
INDUCTION TREATMENT FOLLOWED BY IMMUNOSUPPRESSION WITHDRAWAL IN LIVER TRANSPLANTATION: A COMPARATIVE TRIAL.Tratamiento de inducción y retirada de la inmunosupresión en el trasplante hepático. Estudio comparativo - ATEGE_LIVERiver transplantationEUCTR2005-005635-10-ESiver Unit, ICMD, Hospital Clinic Barcelona